Derek joined UNITY because he believes the innovative approach to cellular senescence will open opportunities for extending healthspan by addressing high unmet patient needs across many age-related diseases.
Derek started his career in 2002 at Celgene as Director of Technical Operations in the Cellular Therapeutics Division, where he directed product development efforts for hematopoietic progenitor cells for the treatment of hematological oncology indications. He then served at Amgen in Global Program Management for early and late stage oncology and dermatology programs and was closely involved in the clinical development and approval of Nplate® and XGEVA®. He later served as Planning and Operations Director in Inflammation, managing licensing and partnership activities and contributing to the development of dermatology global strategy. Derek then served as Senior Director of Gilead’s Portfolio and Project Management group in Liver Diseases that supported the development and approval of Epclusa®, Vosevei® and Vemlidy® for the treatment of chronic hepatitis. He also supported clinical development, regulatory and commercial strategies for fibrotic liver diseases.
Derek received his Ph.D. in Human Medical Genetics and his Masters in Science in Animal Genetics from Louisiana State University, and an MBA from University of New Orleans. Derek joined UNITY in October 2017 as the Vice President of Product Team Leadership.